Latest News
Press background on Cipla Limited
Company profile
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2013-14 was 1.7 billion USD
 Recent press releases
Cipla Announces a Distribution Agreement with Serum Institute of India for Affordable Paediatric Vaccines in Europe

Cipla Europe NV (“Cipla”), a global pharmaceutical company is delighted to announce that it has signed a distribution agreement with Serum Institute of India Ltd. (SII) – a global leader in the production of vaccines. Under the agreement, SII will develop and  manufa... (more)
Share
Cipla Enters Into a Licensing Agreement with Gilead to Increase Access to Hepatitis C Treatment

Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients today announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of Sofosbuvir mono... (more)
Share